April 14, 2021 -- Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources to accelerate the development of its mRNA vaccine platforms.
In addition to highlighting the advantages of these types of vaccines, the company announced that its seven-month data for its cytomegalovirus (CMV) vaccine candidate show that all its measures of neutralizing antibody geometric mean titers (GMTs) are at or above CMV seropositive baselines. A phase III study will evaluate the vaccine in about 8,000 participants in 2021.
Also, interim analysis of a phase I vaccine candidate (mRNA-1345) for respiratory syncytial virus (RSV) shows a greater than elevenfold increase in RSV-neutralizing antibodies in individuals between the ages of 18 and 49. Participants tolerated 50-µg and 100-µg dose levels well.
Lastly, Moderna plans to begin a phase I study evaluating HIV mRNA vaccine candidates, as well as a phase I clinical study of an mRNA flu vaccine candidate in 2021. To date, the company has started clinical trials for 14 different mRNA vaccine candidates.
Copyright © 2021 scienceboard.net